Behcet Disease in New Zealand: Symptoms, Causes & Treatment | aihealz
Rheumatologysevere
Behcet Disease.Care & specialists in New Zealand
In New Zealand, behcet Disease is managed by rheumatologists. Behcet disease (Behcet syndrome) is a chronic systemic vasculitis affecting blood vessels of all sizes and types, characterized by recurrent oral ulcers, genital ulcers, ocular inflammation, and skin lesions, sometimes with arthritis, vascular, gastrointestinal, or central nervous system involvement. Prevalence is highest along the historic Silk Road, with rates of 80-420 per 100,000 in Turkey and 50-150 per 100,000 in Iran, Iraq, Japan, and Korea, falling to 0.3-7 per 100,000 in northern Europe and the United States.
Behcet disease (ICD-10: M35.2) is a systemic variable-vessel vasculitis of unknown cause, classified among autoinflammatory and autoimmune disorders, in which dysregulated innate and adaptive immunity produces neutrophil-rich inflammation in mucocutaneous, ocular, articular, vascular, gastrointestinal, and neurological tissues. The genetic background is strongly associated with HLA-B*51 (carriage in 50-70% of patients in endemic countries versus 10-20% of controls); other susceptibility loci include ERAP1, IL10, and IL23R-IL12RB2. Environmental triggers (streptococcal antigens, herpes simplex virus, gut microbial dysbiosis) interact with this genetic background to produce hyperactive Th1, Th17, and gamma-delta T-cell responses, IL-17 and TNF-alpha elevation, and pathergic neutrophil hyperreactivity. The 2014 International Criteria for Behcet's Disease (ICBD) uses a points-based score combining recurrent oral ulcers, genital ulcers, ocular lesions (uveitis or retinal vasculitis), skin lesions (pseudofolliculitis, erythema nodosum), vascular involvement (deep vein thrombosis, large vessel aneurysm), neurological involvement, and a positive pathergy test.
key facts
Prevalence
Highest in Turkey (80-420 per 100,000), Iran (50-150), Japan (10-15), Korea (8-12); lowest in northern Europe and United States (under 1-7 per 100,000)
Demographics
Equal sex ratio in most cohorts; men have more severe ocular, vascular, and CNS disease; women have more genital ulcers and erythema nodosum
Avg. age
Onset typically age 20-40; juvenile Behcet under age 16 accounts for under 5% of cases
Global cases
Estimated 1-2 million people worldwide; clinical phenotype varies geographically and by ethnicity
Specialist
Rheumatology
§ 02
How you might notice it
The key symptoms of Behcet Disease are: Painful recurrent oral aphthous ulcers — typically more than 3 episodes per year — located on the buccal mucosa, tongue, lips, and palate; ulcers heal in 1-3 weeks usually without scarring., Painful genital ulcers — on the scrotum, vulva, or perianal area — that are typically larger than oral ulcers and may scar., Acute uveitis with eye pain, redness, photophobia, blurred vision, and floaters; can be anterior, posterior, or both, often bilateral., Papulopustular skin lesions resembling folliculitis or acne but in unusual distribution (back, buttocks, lower limbs); positive pathergy with a sterile pustule developing within 24-48 hours at a needle prick site., Erythema nodosum-like tender red nodules on the legs, healing with hyperpigmentation., Non-erosive oligoarticular arthritis affecting knees, ankles, wrists, and elbows; symmetrical or asymmetrical, often resolving spontaneously over weeks., Deep vein thrombosis of the legs or upper extremities, recurrent superficial thrombophlebitis, and venous insufficiency..
01Painful recurrent oral aphthous ulcers — typically more than 3 episodes per year — located on the buccal mucosa, tongue, lips, and palate; ulcers heal in 1-3 weeks usually without scarring.
02Painful genital ulcers — on the scrotum, vulva, or perianal area — that are typically larger than oral ulcers and may scar.
03Acute uveitis with eye pain, redness, photophobia, blurred vision, and floaters; can be anterior, posterior, or both, often bilateral.
04Papulopustular skin lesions resembling folliculitis or acne but in unusual distribution (back, buttocks, lower limbs); positive pathergy with a sterile pustule developing within 24-48 hours at a needle prick site.
§ 03
How it’s diagnosed
diagnosis
Diagnosis is clinical and based on internationally agreed criteria; no single laboratory or imaging test is pathognomonic. The 1990 International Study Group criteria require recurrent oral ulcers (at least 3 episodes per year) plus 2 of: recurrent genital ulcers, ocular lesions (uveitis or retinal vasculitis), defined skin lesions (pseudofolliculitis, erythema nodosum), or positive pathergy test. The 2014 International Criteria for Behcet's Disease (ICBD) introduces a points-based system with greater sensitivity (94%) and similar specificity. A pathergy test — sterile pustule formation within 24-48 hours at a needle prick site — is highly specific in endemic populations but has variable sensitivity. HLA-B*51 genotyping supports the diagnosis in equivocal cases but is neither necessary nor sufficient. Comprehensive evaluation at diagnosis includes complete blood count, ESR, CRP, urinalysis, comprehensive metabolic panel, slit-lamp and dilated fundus examination by ophthalmology, and screening for vascular and neurological involvement based on symptoms. CT or MR angiography is indicated for suspected vascular involvement; MRI brain for suspected neuro-Behcet; ileocolonoscopy for gastrointestinal symptoms. Differential diagnosis includes complex aphthosis without systemic features, herpes simplex, Crohn's disease, MAGIC syndrome (mouth and genital ulcers with inflamed cartilage), lupus, reactive arthritis, and inflammatory bowel disease. Activity is assessed periodically with the Behcet Disease Current Activity Form (BDCAF) and organ-specific damage indices. Patients are stratified by phenotype to guide treatment intensity.
Key tests
01
International Criteria for Behcet's Disease (ICBD 2014) clinical assessmentReference framework for diagnosis; points-based scoring of mucocutaneous, ocular, vascular, neurological, and pathergy features
02
Pathergy test (sterile needle prick of forearm skin)Identifies hyperreactivity to minor trauma — positive when a sterile pustule develops within 24-48 hours at the needle prick site
§ 04
Treatment & cost
medical treatments
✓Colchicine 0.5-1.5 mg/day in divided doses
✓Apremilast 30 mg twice daily
✓Azathioprine 2-3 mg/kg/day
✓Cyclosporine 2-5 mg/kg/day
surgical options
Vascular surgery for pulmonary or abdominal aneurysmsOperative survival 80-90% in specialist centers; high pseudoaneurysm rate (20-30%) without aggressive immunosuppression
Bowel resection for refractory or perforated gastrointestinal BehcetInitial symptom relief in 75-85%; postoperative recurrence in 30-50% at 5 years without biologic therapy
Cataract surgery and vitrectomy for ocular complicationsVisual improvement in 70-85% of selected patients; reduced visual outcomes when retinal damage is established
Joint and cartilage surgeryVariable; uncommon indication
§ 05
Causes & risk factors
known causes
Genetic susceptibility, particularly HLA-B*51
HLA-B*51 carriage is present in 50-70% of patients in Turkey, Iran, and Japan versus 10-20% of healthy controls. The relative risk for HLA-B*51 carriers is 5-7 fold. Other susceptibility loci (ERAP1, IL10, IL23R-IL12RB2, MEFV) modify disease expression and severity.
Innate immune dysregulation
Enhanced neutrophil activity (chemotaxis, superoxide generation), inflammasome activation with IL-1 beta release, and dysfunctional regulatory T-cells produce the characteristic neutrophil-rich vasculitis. This places Behcet at the interface of autoinflammatory and autoimmune disease.
Adaptive immune dysregulation
Th1 and Th17 cell hyperactivity, IFN-gamma and IL-17 elevation, and clonal expansion of gamma-delta T-cells drive the persistent inflammation. TNF-alpha is elevated in active disease and is a key therapeutic target.
Environmental triggers
Streptococcus sanguinis and oral microbial dysbiosis have been proposed as triggers in genetically susceptible hosts. Herpes simplex virus infection and gut microbiome shifts also correlate with disease activity. No single trigger has been confirmed; current models suggest a polygenic-environment interaction.
Geographic and ethnic clustering
Behcet disease is concentrated along the historic Silk Road from the Mediterranean to East Asia, mirroring HLA-B*51 distribution. Migration studies suggest both genetic and environmental contributions: prevalence rises in second-generation migrants from endemic countries but remains lower than in their countries of origin.
risk factors
HLA-B*51 carriagegenetic
§ 06
Living with it
01Maintain rigorous oral hygiene with regular dental review; oral microbial dysbiosis correlates with disease activity.
02Stop smoking; smoking aggravates oral ulcers and increases vascular risk.
03Vaccinate against influenza, pneumococcus, hepatitis B, and herpes zoster before starting immunosuppression where possible.
04Maintain medication adherence to suppress disease activity and prevent organ damage; early treatment reduces damage accrual.
05Avoid medications known to trigger ulcers (NSAIDs in some patients, certain antibiotics) where possible.
06Attend regular ophthalmology and rheumatology follow-up to detect subclinical disease activity.
•Anti-inflammatory Mediterranean-style diet with vegetables, oily fish, and whole grains
•
§ 07
When to seek help
why see a rheumatology
Behcet disease is rare in non-endemic countries and frequently misdiagnosed. Rheumatology assessment confirms the diagnosis, stages organ involvement, and initiates organ-specific therapy. Ophthalmology, vascular surgery, neurology, and gastroenterology involvement is essential when their respective organs are affected; multidisciplinary specialist clinics produce the best outcomes.
01Blindness from ocular Behcet — historically 25% within 5 years; modern therapy has reduced to under 5% in specialist centers.
02Pulmonary artery aneurysm rupture — leading cause of disease-specific mortality; presents with hemoptysis or sudden death.
03Deep vein thrombosis, Budd-Chiari syndrome, and superior vena cava syndrome from extensive venous involvement.
04Cerebral venous sinus thrombosis with raised intracranial pressure and seizures.
05Parenchymal neuro-Behcet with brainstem syndromes, hemiparesis, cerebellar ataxia, and behavioral changes; significant disability in 25-50% of affected patients.
06Intestinal perforation, bleeding, and stricture in gastrointestinal Behcet, often requiring surgery and long-term immunosuppression.
Mucocutaneous Behcet (mild form)Recurrent oral and genital ulcers with skin lesions (papulopustular, erythema nodosum) and joint involvement. Affects roughly 90% of patients and is usually managed with topical therapy, colchicine, and short-course corticosteroids.
Ocular BehcetAnterior, posterior, or panuveitis with retinal vasculitis. Affects 50-70% of patients overall, more severe and bilateral in men. Untreated severe disease causes blindness in up to 25% within 5 years. Requires systemic immunosuppression.
Vascular Behcet (angio-Behcet)Deep vein thrombosis, superficial thrombophlebitis, pulmonary artery aneurysms, abdominal aortic aneurysms, and cerebral venous sinus thrombosis. Affects 15-40% of male patients. Pulmonary aneurysm rupture is the leading cause of disease-specific mortality.
Neurological Behcet (neuro-Behcet)Parenchymal involvement (brainstem, basal ganglia, spinal cord) causes pyramidal signs, cerebellar ataxia, behavioral changes, and seizures. Non-parenchymal involvement is dominated by cerebral venous sinus thrombosis. Occurs in 5-15% and carries substantial morbidity.
Gastrointestinal BehcetDiscrete ileocecal ulcers mimicking Crohn's disease, with abdominal pain, diarrhea, bleeding, and perforation. More common in Japan, Korea, and China than the Mediterranean. Requires aggressive immunosuppression and sometimes surgery.
Juvenile BehcetOnset before age 16. Family clustering more common. Recurrent oral ulcers may precede multi-system disease by years. Diagnostic delay is common because pediatric criteria are less validated.
Living with Behcet Disease
Timeline
Mucocutaneous flares: ulcers heal in 1-3 weeks. Acute uveitis episodes: 4-12 weeks to resolution with treatment. Vascular events: 3-12 months of intensive immunosuppression with prolonged maintenance. Neurological parenchymal disease: months to years; permanent damage is common but not universal. Maintenance therapy is lifelong in most patients.
Lifestyle
01Take medications at the same times daily and complete prescribed monitoring (CBC, LFTs, blood pressure, renal function).
02Use topical analgesic mouthwashes (lidocaine 2%) and barrier preparations for active oral ulcers.
03Wear sunglasses with UV protection to reduce photophobia and ocular discomfort during uveitis flares.
04Avoid contact lens use during active ocular inflammation.
05Use barrier contraception until partner-relevant infections are excluded; genital ulcers can be confused with herpes.
06Carry a medical alert card listing Behcet disease, immunosuppressants, and any history of vascular or neurological involvement.
Daily management
01Take medications at the same times daily; biologic injections per the prescribed schedule.
02
Complementary approaches
Thalidomide 100-300 mg dailyEffective for severe refractory mucocutaneous Behcet. Restricted by teratogenicity and peripheral neuropathy; usually reserved for men or postmenopausal women under structured monitoring.
Mycophenolate mofetil 2-3 g dailyUsed as steroid-sparing therapy in selected patients with ocular, neurological, or gastrointestinal disease intolerant of azathioprine. Modest evidence base in Behcet specifically.
Choosing a doctor
Choose a rheumatologist with documented experience in vasculitis or Behcet disease, ideally working in a tertiary center with on-site ophthalmology, vascular surgery, and neurology. Multidisciplinary Behcet clinics improve diagnostic accuracy and treatment escalation, with measurable reductions in blindness and major organ damage.
Behcet disease is a chronic inflammatory condition affecting blood vessels of all sizes, causing recurrent mouth and genital ulcers, eye inflammation, skin lesions, and sometimes joint, vascular, gut, or brain involvement. It is most common in countries along the historic Silk Road.
What are the symptoms of Behcet disease?▾▴
Hallmark symptoms are recurrent painful oral and genital ulcers, eye inflammation (uveitis), pustular skin lesions, and arthritis. Some patients also have deep vein thrombosis, intestinal ulcers, or neurological involvement. Symptoms typically come in flares lasting weeks to months.
How is Behcet disease diagnosed?▾▴
Diagnosis is clinical, based on International Criteria for Behcet's Disease (ICBD 2014) requiring recurrent oral ulcers plus features such as genital ulcers, eye lesions, skin lesions, vascular involvement, or positive pathergy test. HLA-B*51 testing supports the diagnosis in equivocal cases.
Is Behcet disease an autoimmune disease?▾▴
Behcet disease has features of both autoimmune and autoinflammatory diseases. It involves dysregulated innate immunity (hyperactive neutrophils) and adaptive immunity (Th1 and Th17 cells) without specific autoantibodies seen in classical autoimmune diseases like lupus.
What causes Behcet disease?▾▴
Behcet disease is caused by complex interactions between genetic factors (especially HLA-B*51) and environmental triggers including streptococcal antigens, herpes simplex virus, and oral microbial dysbiosis. No single cause has been identified.
How is Behcet disease treated?▾▴
Treatment is organ-specific. Mucocutaneous and joint disease respond to colchicine, apremilast, and corticosteroids. Ocular, vascular, neurological, and gastrointestinal involvement require immunosuppression with azathioprine, cyclosporine, interferon-alpha, or TNF-alpha inhibitors. Treatment is lifelong.
Can Behcet disease be cured?▾▴
There is no cure for Behcet disease, but it can be effectively controlled. Most patients achieve symptom relief and prevention of major organ damage with modern immunosuppression. Disease activity typically declines after the first 7 years; some patients enter prolonged remission.
Is Behcet disease genetic?▾▴
Genetic factors contribute but Behcet is not inherited in a Mendelian pattern. HLA-B*51 carriage increases risk 5-7 fold but is not necessary or sufficient. Family clustering is common but most patients have no affected relatives. Multiple susceptibility genes interact with environmental factors.
Where is Behcet disease most common?▾▴
Behcet disease is most common along the historic Silk Road from the Mediterranean to East Asia. Prevalence is highest in Turkey (80-420 per 100,000), Iran, Iraq, Japan, and Korea. It is uncommon in northern Europe and North America, though under-recognized in migrant populations.
Can Behcet disease cause blindness?▾▴
Ocular Behcet historically caused blindness in 25% of patients within 5 years. Modern treatment with biologic therapies has reduced this risk to under 5% in specialist centers. Early diagnosis and aggressive immunosuppression are key to preserving vision.
What is the pathergy test?▾▴
The pathergy test involves a sterile needle prick of the forearm skin. A positive result is a sterile pustule developing within 24-48 hours, indicating hyperreactivity to minor trauma. The test is highly specific but variably sensitive, with higher positivity rates in Mediterranean and East Asian patients.
Does HLA-B*51 cause Behcet disease?▾▴
HLA-B*51 increases susceptibility 5-7 fold but does not directly cause Behcet. It is carried by 50-70% of patients in endemic countries versus 10-20% of healthy individuals. Other genetic and environmental factors are necessary for disease expression.
Can Behcet disease affect the brain?▾▴
Yes. Neurological Behcet (neuro-Behcet) affects 5-15% of patients and can produce brainstem syndromes, hemiparesis, cerebellar ataxia, seizures, behavioral changes, and cerebral venous sinus thrombosis. Treatment requires high-dose immunosuppression including TNF-alpha inhibitors in severe cases.
Is colchicine effective for Behcet?▾▴
Yes. Colchicine 0.5-1.5 mg daily reduces oral and genital ulcer frequency in 50-70% of patients and is particularly effective in women. It is first-line for mucocutaneous and articular disease. Side effects (diarrhea, abdominal cramps) may limit dose escalation.
What is apremilast?▾▴
Apremilast is a phosphodiesterase 4 inhibitor taken 30 mg twice daily and FDA-approved (2019) for Behcet's oral ulcers. It significantly reduces oral ulcer count in randomized trials (RELIEF) with response in 65-75% of patients at 12 weeks. Side effects include diarrhea, nausea, and headache.
Can pregnancy affect Behcet disease?▾▴
Pregnancy outcomes are generally favorable when disease is controlled. Some patients experience flares during pregnancy or postpartum; others enter remission. Medication review is essential to avoid teratogens (thalidomide, methotrexate, mycophenolate). Azathioprine, hydroxychloroquine, and certain biologics can be continued.
What is the prognosis for Behcet disease?▾▴
Mucocutaneous Behcet has an excellent prognosis with normal life expectancy. Ocular Behcet, vascular, neurological, and gastrointestinal involvement carry higher morbidity and mortality. Standardized mortality ratio is 1.4-1.7 in Turkish cohorts. Young men with severe systemic involvement have the worst outcomes.
Can Behcet disease cause blood clots?▾▴
Yes. Vascular Behcet causes deep vein thrombosis, superficial thrombophlebitis, Budd-Chiari syndrome, and cerebral venous sinus thrombosis in 15-40% of patients. Treatment combines immunosuppression with anticoagulation in most venous events, but anticoagulation is avoided in pulmonary artery aneurysms.
Are there TNF blockers for Behcet?▾▴
Yes. TNF-alpha inhibitors (infliximab, adalimumab) are highly effective for severe ocular, vascular, neurological, and gastrointestinal Behcet. Response rates are 60-80% in refractory disease. They are increasingly used as first-line for major organ involvement.
Is Behcet disease contagious?▾▴
No. Behcet disease is not contagious. It cannot be transmitted between people. Genetic susceptibility and environmental triggers cause disease in predisposed individuals. Family members may be at higher risk because of shared genetics rather than transmission.
How do I find a specialist for Behcet disease?▾▴
Look for a rheumatologist with documented experience in vasculitis, ideally at a tertiary center with multidisciplinary Behcet or vasculitis clinic. National patient organizations (American Behcet's Disease Association, Behcet's UK) maintain specialist directories. Multidisciplinary care improves outcomes significantly.
05Erythema nodosum-like tender red nodules on the legs, healing with hyperpigmentation.
06Non-erosive oligoarticular arthritis affecting knees, ankles, wrists, and elbows; symmetrical or asymmetrical, often resolving spontaneously over weeks.
07Deep vein thrombosis of the legs or upper extremities, recurrent superficial thrombophlebitis, and venous insufficiency.
08Headache, focal neurological deficits, cerebellar ataxia, cranial nerve palsies, behavioral changes, or seizures in neuro-Behcet.
09Abdominal pain, diarrhea (sometimes bloody), weight loss, and intestinal perforation in gastrointestinal Behcet.
10Hemoptysis, chest pain, dyspnea, or sudden death from pulmonary artery aneurysm rupture in vascular Behcet.
early warning signs
•Recurrent oral ulcers (3 or more episodes per year) without other explanation
•Genital ulceration in a young adult, especially with prior oral ulcers
•Acute eye redness, pain, and blurred vision in a person of Mediterranean, Middle Eastern, or East Asian descent
•Pustular acne-like skin lesions in unusual locations (back, buttocks)
•New deep vein thrombosis in a young adult without other risk factors
● emergency signs
•Sudden severe headache, vision loss, or focal neurological signs — exclude cerebral venous sinus thrombosis or parenchymal CNS Behcet
•Hemoptysis with chest pain in a young patient — consider pulmonary artery aneurysm
•Severe abdominal pain with peritonism — possible bowel perforation
•Acute painful red eye with vision loss — sight-threatening uveitis requiring urgent ophthalmology assessment
•Acute severe limb swelling with discoloration suggesting extensive deep vein thrombosis or arterial aneurysm rupture
03
HLA-B*51 genotypingSupportive evidence in equivocal cases; positivity raises pre-test probability in patients from endemic regions
04
Comprehensive ophthalmologic examination (slit-lamp, dilated fundus, fluorescein angiography)Detects subclinical uveitis and retinal vasculitis even when patients are asymptomatic
05
CT/MR angiography of chest, abdomen, and pelvisIdentifies pulmonary artery aneurysms, abdominal aortic aneurysms, deep vein thromboses, and Budd-Chiari syndrome
06
MRI brain and spinal cord with contrastIdentifies parenchymal neuro-Behcet lesions (brainstem, basal ganglia, spinal cord) and cerebral venous sinus thrombosis
Outlook
Long-term outcomes vary by phenotype, age at onset, and access to modern immunosuppression. Mucocutaneous Behcet has an excellent prognosis with normal life expectancy and minimal long-term damage when treated. Ocular Behcet without biologic therapy led to blindness in 25% within 5 years in historic cohorts; modern treatment has reduced this to under 5% in specialist clinics. Vascular and neurological involvement carry the highest mortality: untreated pulmonary artery aneurysms have a 5-year mortality of 25-50%; cyclophosphamide and TNF-alpha inhibitors have improved this substantially. Disease activity typically peaks in the first 7 years and declines thereafter, although organ damage accrues over decades. Standardized mortality ratio in Behcet is 1.4-1.7 in Turkish cohorts, with vascular and neurological complications being the dominant causes of premature death. Young men with onset under 25 have the worst prognosis. Pregnancy outcomes are generally favorable with disease control; medication adjustments (avoiding teratogens) are essential.
Strongest genetic risk factor, with 5-7 fold increased relative risk. Carriage rates are 50-70% in Turkish, Iranian, and Japanese patients versus 10-20% in matched healthy controls.
Family history of Behcet diseasenon-modifiable
First-degree relatives have a 2-10 fold increased risk. Family clustering is more common in juvenile-onset disease. Familial cases tend to be more severe.
Ancestry from Silk Road regions (Turkey, Iran, Japan, Korea, China)non-modifiable
Prevalence in Turkey reaches 420 per 100,000 versus under 7 per 100,000 in northern Europe and the United States. Ancestry from endemic regions raises baseline risk.
Male sexnon-modifiable
Men have similar overall prevalence but more severe ocular, vascular, and CNS disease and higher mortality. Onset under age 25 with male sex is the most adverse prognostic profile.
Age 20-40 yearsnon-modifiable
Most patients present in the third or fourth decade. Onset over age 50 is uncommon and may predict milder disease.
Smoking and oral healthmodifiable
Smoking and poor oral hygiene increase oral ulcer frequency and severity. Smoking cessation and structured dental care reduce flare frequency in observational cohorts.
Streptococcal infection and oral microbial dysbiosismodifiable
Streptococcus sanguinis and altered oral microbiome composition are associated with disease activity. Penicillin prophylaxis is sometimes used to reduce oral ulcer frequency.
Calcium and vitamin D for bone protection during corticosteroid therapy
•Adequate hydration (at least 2 L water daily) particularly when ulcers limit fluid intake
foods to avoid
•Acidic foods (citrus, tomato, vinegar) during active oral ulcers
•Spicy foods and rough-textured foods (crusty bread, hard chips) during flares
•Excess salt and processed foods during corticosteroid therapy
•Grapefruit juice when on cyclosporine or tacrolimus
07Steroid-induced osteoporosis, diabetes, cataract, and adrenal insufficiency from prolonged corticosteroid exposure — anticipated and managed proactively.
choosing the right hospital
01Multidisciplinary Behcet or vasculitis clinic
02Ophthalmology service with fluorescein angiography and intravitreal therapy capability
03Vascular surgery and interventional radiology services
04Neurology with MRI and CSF analysis capability
05Biologic and infusion services for TNF-alpha and IL-1 inhibitor therapy
Essential facilities
Tertiary rheumatology and vasculitis centersUveitis clinics with biologic therapy infrastructureVascular surgery and endovascular servicesNeurology and stroke services for neuro-BehcetInflammatory bowel disease clinics for intestinal Behcet
Inspect mouth, genitals, and skin daily during active disease for new ulcers or lesions.
03Track flares, symptoms, and medication side effects in a simple diary.
04Use prescribed topical therapies (corticosteroid pastes, anesthetic gels) for new ulcers.
05Monitor blood pressure, blood glucose, and weight while on corticosteroids.
06Maintain regular dental hygiene with soft-bristled toothbrush during ulcer flares.
Exercise
Regular moderate aerobic activity (walking, swimming, cycling) is recommended during remission. Avoid contact sports during anticoagulation. Patients with ocular inflammation should avoid activities risking eye trauma. Cardiac rehabilitation is recommended after vascular interventions.